nodes	percent_of_prediction	percent_of_DWPC	metapath
Lisuride—HTR2B—Sorafenib—kidney cancer	0.117	0.184	CbGbCtD
Lisuride—HTR2C—Sorafenib—kidney cancer	0.0765	0.12	CbGbCtD
Lisuride—CYP2D6—Temsirolimus—kidney cancer	0.0752	0.118	CbGbCtD
Lisuride—CYP3A4—Everolimus—kidney cancer	0.0708	0.111	CbGbCtD
Lisuride—CYP3A4—Temsirolimus—kidney cancer	0.0478	0.0749	CbGbCtD
Lisuride—CYP2D6—Pazopanib—kidney cancer	0.0395	0.0619	CbGbCtD
Lisuride—CYP2D6—Erlotinib—kidney cancer	0.0282	0.0442	CbGbCtD
Lisuride—CYP3A4—Pazopanib—kidney cancer	0.0251	0.0394	CbGbCtD
Lisuride—CYP2D6—Sorafenib—kidney cancer	0.0229	0.0359	CbGbCtD
Lisuride—CYP2D6—Vinblastine—kidney cancer	0.0226	0.0355	CbGbCtD
Lisuride—CYP3A4—Erlotinib—kidney cancer	0.0179	0.0281	CbGbCtD
Lisuride—CYP3A4—Paclitaxel—kidney cancer	0.0164	0.0257	CbGbCtD
Lisuride—CYP3A4—Sorafenib—kidney cancer	0.0146	0.0228	CbGbCtD
Lisuride—CYP3A4—Vinblastine—kidney cancer	0.0144	0.0226	CbGbCtD
Lisuride—CYP3A4—Vincristine—kidney cancer	0.0142	0.0222	CbGbCtD
Lisuride—CYP2D6—Doxorubicin—kidney cancer	0.0139	0.0218	CbGbCtD
Lisuride—CYP3A4—Sunitinib—kidney cancer	0.0118	0.0185	CbGbCtD
Lisuride—CYP3A4—Doxorubicin—kidney cancer	0.00885	0.0139	CbGbCtD
Lisuride—Gastrointestinal disorder—Pazopanib—kidney cancer	0.00091	0.00302	CcSEcCtD
Lisuride—Fatigue—Pazopanib—kidney cancer	0.000908	0.00302	CcSEcCtD
Lisuride—Cardiac disorder—Sunitinib—kidney cancer	0.000908	0.00302	CcSEcCtD
Lisuride—Pleural effusion—Doxorubicin—kidney cancer	0.000904	0.003	CcSEcCtD
Lisuride—Palpitations—Everolimus—kidney cancer	0.000901	0.00299	CcSEcCtD
Lisuride—Mental disorder—Sorafenib—kidney cancer	0.000891	0.00296	CcSEcCtD
Lisuride—Cough—Everolimus—kidney cancer	0.00089	0.00296	CcSEcCtD
Lisuride—Angiopathy—Sunitinib—kidney cancer	0.000887	0.00295	CcSEcCtD
Lisuride—Malnutrition—Sorafenib—kidney cancer	0.000885	0.00294	CcSEcCtD
Lisuride—Sweating—Vincristine—kidney cancer	0.000884	0.00294	CcSEcCtD
Lisuride—Immune system disorder—Sunitinib—kidney cancer	0.000883	0.00294	CcSEcCtD
Lisuride—Dehydration—Paclitaxel—kidney cancer	0.000883	0.00294	CcSEcCtD
Lisuride—Syncope—Erlotinib—kidney cancer	0.000882	0.00293	CcSEcCtD
Lisuride—Mediastinal disorder—Sunitinib—kidney cancer	0.000882	0.00293	CcSEcCtD
Lisuride—Orthostatic hypotension—Paclitaxel—kidney cancer	0.000868	0.00288	CcSEcCtD
Lisuride—Anxiety—Everolimus—kidney cancer	0.000865	0.00287	CcSEcCtD
Lisuride—Cough—Erlotinib—kidney cancer	0.000858	0.00285	CcSEcCtD
Lisuride—Mental disorder—Sunitinib—kidney cancer	0.000857	0.00285	CcSEcCtD
Lisuride—Malnutrition—Sunitinib—kidney cancer	0.000851	0.00283	CcSEcCtD
Lisuride—Dry mouth—Everolimus—kidney cancer	0.000849	0.00282	CcSEcCtD
Lisuride—Sweating—Gemcitabine—kidney cancer	0.000838	0.00279	CcSEcCtD
Lisuride—Anxiety—Erlotinib—kidney cancer	0.000834	0.00277	CcSEcCtD
Lisuride—Infection—Everolimus—kidney cancer	0.000827	0.00275	CcSEcCtD
Lisuride—Hallucination—Vincristine—kidney cancer	0.000823	0.00274	CcSEcCtD
Lisuride—Nervous system disorder—Everolimus—kidney cancer	0.000816	0.00271	CcSEcCtD
Lisuride—Tachycardia—Everolimus—kidney cancer	0.000812	0.0027	CcSEcCtD
Lisuride—Hyperhidrosis—Everolimus—kidney cancer	0.000804	0.00267	CcSEcCtD
Lisuride—Asthenia—Temsirolimus—kidney cancer	0.000802	0.00267	CcSEcCtD
Lisuride—Infection—Erlotinib—kidney cancer	0.000797	0.00265	CcSEcCtD
Lisuride—Anorexia—Vinblastine—kidney cancer	0.000796	0.00265	CcSEcCtD
Lisuride—Syncope—Sorafenib—kidney cancer	0.000794	0.00264	CcSEcCtD
Lisuride—Anorexia—Everolimus—kidney cancer	0.000793	0.00264	CcSEcCtD
Lisuride—Nervous system disorder—Erlotinib—kidney cancer	0.000787	0.00262	CcSEcCtD
Lisuride—Disturbance in sexual arousal—Capecitabine—kidney cancer	0.000773	0.00257	CcSEcCtD
Lisuride—Oedema peripheral—Gemcitabine—kidney cancer	0.000773	0.00257	CcSEcCtD
Lisuride—Cough—Sorafenib—kidney cancer	0.000772	0.00257	CcSEcCtD
Lisuride—Cardiac disorder—Vincristine—kidney cancer	0.000768	0.00255	CcSEcCtD
Lisuride—Anorexia—Erlotinib—kidney cancer	0.000765	0.00254	CcSEcCtD
Lisuride—Asthenia—Pazopanib—kidney cancer	0.000756	0.00251	CcSEcCtD
Lisuride—Insomnia—Everolimus—kidney cancer	0.000752	0.0025	CcSEcCtD
Lisuride—Angiopathy—Vincristine—kidney cancer	0.000751	0.00249	CcSEcCtD
Lisuride—Weight increased—Paclitaxel—kidney cancer	0.000747	0.00248	CcSEcCtD
Lisuride—Mediastinal disorder—Vincristine—kidney cancer	0.000746	0.00248	CcSEcCtD
Lisuride—Cough—Sunitinib—kidney cancer	0.000743	0.00247	CcSEcCtD
Lisuride—Weight decreased—Paclitaxel—kidney cancer	0.000743	0.00247	CcSEcCtD
Lisuride—Dyspnoea—Everolimus—kidney cancer	0.000742	0.00246	CcSEcCtD
Lisuride—Somnolence—Everolimus—kidney cancer	0.00074	0.00246	CcSEcCtD
Lisuride—Dizziness—Temsirolimus—kidney cancer	0.00074	0.00246	CcSEcCtD
Lisuride—Dry mouth—Sorafenib—kidney cancer	0.000737	0.00245	CcSEcCtD
Lisuride—Cardiac disorder—Gemcitabine—kidney cancer	0.000728	0.00242	CcSEcCtD
Lisuride—Insomnia—Erlotinib—kidney cancer	0.000726	0.00241	CcSEcCtD
Lisuride—Decreased appetite—Vinblastine—kidney cancer	0.000726	0.00241	CcSEcCtD
Lisuride—Dehydration—Capecitabine—kidney cancer	0.000725	0.00241	CcSEcCtD
Lisuride—Mental disorder—Vincristine—kidney cancer	0.000725	0.00241	CcSEcCtD
Lisuride—Decreased appetite—Everolimus—kidney cancer	0.000723	0.0024	CcSEcCtD
Lisuride—Gastrointestinal disorder—Everolimus—kidney cancer	0.000718	0.00239	CcSEcCtD
Lisuride—Infection—Sorafenib—kidney cancer	0.000717	0.00238	CcSEcCtD
Lisuride—Fatigue—Everolimus—kidney cancer	0.000717	0.00238	CcSEcCtD
Lisuride—Dyspnoea—Erlotinib—kidney cancer	0.000716	0.00238	CcSEcCtD
Lisuride—Constipation—Vinblastine—kidney cancer	0.000714	0.00237	CcSEcCtD
Lisuride—Angiopathy—Gemcitabine—kidney cancer	0.000712	0.00237	CcSEcCtD
Lisuride—Orthostatic hypotension—Capecitabine—kidney cancer	0.000712	0.00237	CcSEcCtD
Lisuride—Constipation—Everolimus—kidney cancer	0.000711	0.00236	CcSEcCtD
Lisuride—Vomiting—Temsirolimus—kidney cancer	0.000711	0.00236	CcSEcCtD
Lisuride—Dry mouth—Sunitinib—kidney cancer	0.000709	0.00236	CcSEcCtD
Lisuride—Immune system disorder—Gemcitabine—kidney cancer	0.000709	0.00236	CcSEcCtD
Lisuride—Nervous system disorder—Sorafenib—kidney cancer	0.000708	0.00235	CcSEcCtD
Lisuride—Mediastinal disorder—Gemcitabine—kidney cancer	0.000707	0.00235	CcSEcCtD
Lisuride—Headache—Temsirolimus—kidney cancer	0.000701	0.00233	CcSEcCtD
Lisuride—Decreased appetite—Erlotinib—kidney cancer	0.000698	0.00232	CcSEcCtD
Lisuride—Dizziness—Pazopanib—kidney cancer	0.000697	0.00232	CcSEcCtD
Lisuride—Gastrointestinal disorder—Erlotinib—kidney cancer	0.000693	0.0023	CcSEcCtD
Lisuride—Fatigue—Erlotinib—kidney cancer	0.000692	0.0023	CcSEcCtD
Lisuride—Infection—Sunitinib—kidney cancer	0.00069	0.00229	CcSEcCtD
Lisuride—Anorexia—Sorafenib—kidney cancer	0.000688	0.00229	CcSEcCtD
Lisuride—Feeling abnormal—Vinblastine—kidney cancer	0.000688	0.00229	CcSEcCtD
Lisuride—Constipation—Erlotinib—kidney cancer	0.000686	0.00228	CcSEcCtD
Lisuride—Feeling abnormal—Everolimus—kidney cancer	0.000686	0.00228	CcSEcCtD
Lisuride—Nervous system disorder—Sunitinib—kidney cancer	0.000681	0.00226	CcSEcCtD
Lisuride—Vomiting—Pazopanib—kidney cancer	0.00067	0.00223	CcSEcCtD
Lisuride—Anorexia—Sunitinib—kidney cancer	0.000662	0.0022	CcSEcCtD
Lisuride—Headache—Pazopanib—kidney cancer	0.00066	0.00219	CcSEcCtD
Lisuride—Infection—Dactinomycin—kidney cancer	0.000654	0.00217	CcSEcCtD
Lisuride—Oedema peripheral—Paclitaxel—kidney cancer	0.000647	0.00215	CcSEcCtD
Lisuride—Vertigo—Vincristine—kidney cancer	0.000647	0.00215	CcSEcCtD
Lisuride—Abdominal discomfort—Capecitabine—kidney cancer	0.000646	0.00215	CcSEcCtD
Lisuride—Dyspnoea—Sorafenib—kidney cancer	0.000644	0.00214	CcSEcCtD
Lisuride—Insomnia—Sunitinib—kidney cancer	0.000629	0.00209	CcSEcCtD
Lisuride—Decreased appetite—Sorafenib—kidney cancer	0.000628	0.00209	CcSEcCtD
Lisuride—Anorexia—Dactinomycin—kidney cancer	0.000627	0.00208	CcSEcCtD
Lisuride—Gastrointestinal disorder—Sorafenib—kidney cancer	0.000623	0.00207	CcSEcCtD
Lisuride—Fatigue—Sorafenib—kidney cancer	0.000623	0.00207	CcSEcCtD
Lisuride—Dyspnoea—Sunitinib—kidney cancer	0.00062	0.00206	CcSEcCtD
Lisuride—Constipation—Sorafenib—kidney cancer	0.000618	0.00205	CcSEcCtD
Lisuride—Weight increased—Capecitabine—kidney cancer	0.000613	0.00204	CcSEcCtD
Lisuride—Cardiac disorder—Paclitaxel—kidney cancer	0.00061	0.00203	CcSEcCtD
Lisuride—Weight decreased—Capecitabine—kidney cancer	0.00061	0.00203	CcSEcCtD
Lisuride—Decreased appetite—Sunitinib—kidney cancer	0.000604	0.00201	CcSEcCtD
Lisuride—Gastrointestinal disorder—Sunitinib—kidney cancer	0.0006	0.00199	CcSEcCtD
Lisuride—Asthenia—Vinblastine—kidney cancer	0.000599	0.00199	CcSEcCtD
Lisuride—Fatigue—Sunitinib—kidney cancer	0.000599	0.00199	CcSEcCtD
Lisuride—Asthenia—Everolimus—kidney cancer	0.000597	0.00198	CcSEcCtD
Lisuride—Cough—Gemcitabine—kidney cancer	0.000596	0.00198	CcSEcCtD
Lisuride—Angiopathy—Paclitaxel—kidney cancer	0.000596	0.00198	CcSEcCtD
Lisuride—Constipation—Sunitinib—kidney cancer	0.000594	0.00197	CcSEcCtD
Lisuride—Immune system disorder—Paclitaxel—kidney cancer	0.000594	0.00197	CcSEcCtD
Lisuride—Mediastinal disorder—Paclitaxel—kidney cancer	0.000592	0.00197	CcSEcCtD
Lisuride—Infection—Vincristine—kidney cancer	0.000584	0.00194	CcSEcCtD
Lisuride—Nervous system disorder—Vincristine—kidney cancer	0.000576	0.00192	CcSEcCtD
Lisuride—Asthenia—Erlotinib—kidney cancer	0.000576	0.00191	CcSEcCtD
Lisuride—Mental disorder—Paclitaxel—kidney cancer	0.000576	0.00191	CcSEcCtD
Lisuride—Malnutrition—Paclitaxel—kidney cancer	0.000572	0.0019	CcSEcCtD
Lisuride—Decreased appetite—Dactinomycin—kidney cancer	0.000572	0.0019	CcSEcCtD
Lisuride—Hyperhidrosis—Vincristine—kidney cancer	0.000568	0.00189	CcSEcCtD
Lisuride—Fatigue—Dactinomycin—kidney cancer	0.000567	0.00188	CcSEcCtD
Lisuride—Anorexia—Vincristine—kidney cancer	0.00056	0.00186	CcSEcCtD
Lisuride—Infection—Gemcitabine—kidney cancer	0.000554	0.00184	CcSEcCtD
Lisuride—Dizziness—Vinblastine—kidney cancer	0.000552	0.00184	CcSEcCtD
Lisuride—Dizziness—Everolimus—kidney cancer	0.00055	0.00183	CcSEcCtD
Lisuride—Nervous system disorder—Gemcitabine—kidney cancer	0.000547	0.00182	CcSEcCtD
Lisuride—Feeling abnormal—Dactinomycin—kidney cancer	0.000542	0.0018	CcSEcCtD
Lisuride—Hyperhidrosis—Gemcitabine—kidney cancer	0.000539	0.00179	CcSEcCtD
Lisuride—Insomnia—Vincristine—kidney cancer	0.000532	0.00177	CcSEcCtD
Lisuride—Anorexia—Gemcitabine—kidney cancer	0.000532	0.00177	CcSEcCtD
Lisuride—Oedema peripheral—Capecitabine—kidney cancer	0.000531	0.00177	CcSEcCtD
Lisuride—Vomiting—Vinblastine—kidney cancer	0.000531	0.00176	CcSEcCtD
Lisuride—Dizziness—Erlotinib—kidney cancer	0.000531	0.00176	CcSEcCtD
Lisuride—Vomiting—Everolimus—kidney cancer	0.000529	0.00176	CcSEcCtD
Lisuride—Headache—Vinblastine—kidney cancer	0.000523	0.00174	CcSEcCtD
Lisuride—Headache—Everolimus—kidney cancer	0.000521	0.00173	CcSEcCtD
Lisuride—Asthenia—Sorafenib—kidney cancer	0.000518	0.00172	CcSEcCtD
Lisuride—Vertigo—Paclitaxel—kidney cancer	0.000514	0.00171	CcSEcCtD
Lisuride—Syncope—Paclitaxel—kidney cancer	0.000513	0.0017	CcSEcCtD
Lisuride—Decreased appetite—Vincristine—kidney cancer	0.000511	0.0017	CcSEcCtD
Lisuride—Vomiting—Erlotinib—kidney cancer	0.00051	0.0017	CcSEcCtD
Lisuride—Gastrointestinal disorder—Vincristine—kidney cancer	0.000507	0.00169	CcSEcCtD
Lisuride—Fatigue—Vincristine—kidney cancer	0.000507	0.00168	CcSEcCtD
Lisuride—Palpitations—Paclitaxel—kidney cancer	0.000505	0.00168	CcSEcCtD
Lisuride—Insomnia—Gemcitabine—kidney cancer	0.000504	0.00168	CcSEcCtD
Lisuride—Headache—Erlotinib—kidney cancer	0.000503	0.00167	CcSEcCtD
Lisuride—Constipation—Vincristine—kidney cancer	0.000503	0.00167	CcSEcCtD
Lisuride—Cardiac disorder—Capecitabine—kidney cancer	0.0005	0.00166	CcSEcCtD
Lisuride—Cough—Paclitaxel—kidney cancer	0.000499	0.00166	CcSEcCtD
Lisuride—Asthenia—Sunitinib—kidney cancer	0.000499	0.00166	CcSEcCtD
Lisuride—Dyspnoea—Gemcitabine—kidney cancer	0.000497	0.00165	CcSEcCtD
Lisuride—Somnolence—Gemcitabine—kidney cancer	0.000496	0.00165	CcSEcCtD
Lisuride—Angiopathy—Capecitabine—kidney cancer	0.000489	0.00163	CcSEcCtD
Lisuride—Immune system disorder—Capecitabine—kidney cancer	0.000487	0.00162	CcSEcCtD
Lisuride—Mediastinal disorder—Capecitabine—kidney cancer	0.000486	0.00161	CcSEcCtD
Lisuride—Anxiety—Paclitaxel—kidney cancer	0.000485	0.00161	CcSEcCtD
Lisuride—Decreased appetite—Gemcitabine—kidney cancer	0.000485	0.00161	CcSEcCtD
Lisuride—Gastrointestinal disorder—Gemcitabine—kidney cancer	0.000481	0.0016	CcSEcCtD
Lisuride—Fatigue—Gemcitabine—kidney cancer	0.000481	0.0016	CcSEcCtD
Lisuride—Dizziness—Sorafenib—kidney cancer	0.000478	0.00159	CcSEcCtD
Lisuride—Constipation—Gemcitabine—kidney cancer	0.000477	0.00158	CcSEcCtD
Lisuride—Dry mouth—Paclitaxel—kidney cancer	0.000476	0.00158	CcSEcCtD
Lisuride—Mental disorder—Capecitabine—kidney cancer	0.000472	0.00157	CcSEcCtD
Lisuride—Asthenia—Dactinomycin—kidney cancer	0.000472	0.00157	CcSEcCtD
Lisuride—Confusional state—Paclitaxel—kidney cancer	0.000471	0.00156	CcSEcCtD
Lisuride—Malnutrition—Capecitabine—kidney cancer	0.000469	0.00156	CcSEcCtD
Lisuride—Dehydration—Doxorubicin—kidney cancer	0.000467	0.00155	CcSEcCtD
Lisuride—Infection—Paclitaxel—kidney cancer	0.000464	0.00154	CcSEcCtD
Lisuride—Dizziness—Sunitinib—kidney cancer	0.00046	0.00153	CcSEcCtD
Lisuride—Feeling abnormal—Gemcitabine—kidney cancer	0.000459	0.00153	CcSEcCtD
Lisuride—Vomiting—Sorafenib—kidney cancer	0.000459	0.00153	CcSEcCtD
Lisuride—Orthostatic hypotension—Doxorubicin—kidney cancer	0.000459	0.00153	CcSEcCtD
Lisuride—Nervous system disorder—Paclitaxel—kidney cancer	0.000458	0.00152	CcSEcCtD
Lisuride—Tachycardia—Paclitaxel—kidney cancer	0.000456	0.00151	CcSEcCtD
Lisuride—Headache—Sorafenib—kidney cancer	0.000452	0.0015	CcSEcCtD
Lisuride—Hyperhidrosis—Paclitaxel—kidney cancer	0.000451	0.0015	CcSEcCtD
Lisuride—Anorexia—Paclitaxel—kidney cancer	0.000445	0.00148	CcSEcCtD
Lisuride—Vomiting—Sunitinib—kidney cancer	0.000442	0.00147	CcSEcCtD
Lisuride—Headache—Sunitinib—kidney cancer	0.000435	0.00145	CcSEcCtD
Lisuride—Insomnia—Paclitaxel—kidney cancer	0.000422	0.0014	CcSEcCtD
Lisuride—Vertigo—Capecitabine—kidney cancer	0.000422	0.0014	CcSEcCtD
Lisuride—Asthenia—Vincristine—kidney cancer	0.000422	0.0014	CcSEcCtD
Lisuride—Syncope—Capecitabine—kidney cancer	0.000421	0.0014	CcSEcCtD
Lisuride—Vomiting—Dactinomycin—kidney cancer	0.000418	0.00139	CcSEcCtD
Lisuride—Dyspnoea—Paclitaxel—kidney cancer	0.000416	0.00138	CcSEcCtD
Lisuride—Somnolence—Paclitaxel—kidney cancer	0.000415	0.00138	CcSEcCtD
Lisuride—Palpitations—Capecitabine—kidney cancer	0.000415	0.00138	CcSEcCtD
Lisuride—Cough—Capecitabine—kidney cancer	0.00041	0.00136	CcSEcCtD
Lisuride—Decreased appetite—Paclitaxel—kidney cancer	0.000406	0.00135	CcSEcCtD
Lisuride—Gastrointestinal disorder—Paclitaxel—kidney cancer	0.000403	0.00134	CcSEcCtD
Lisuride—Fatigue—Paclitaxel—kidney cancer	0.000402	0.00134	CcSEcCtD
Lisuride—Asthenia—Gemcitabine—kidney cancer	0.0004	0.00133	CcSEcCtD
Lisuride—Constipation—Paclitaxel—kidney cancer	0.000399	0.00133	CcSEcCtD
Lisuride—Anxiety—Capecitabine—kidney cancer	0.000398	0.00132	CcSEcCtD
Lisuride—Weight increased—Doxorubicin—kidney cancer	0.000395	0.00131	CcSEcCtD
Lisuride—Weight decreased—Doxorubicin—kidney cancer	0.000393	0.00131	CcSEcCtD
Lisuride—Dry mouth—Capecitabine—kidney cancer	0.000391	0.0013	CcSEcCtD
Lisuride—Dizziness—Vincristine—kidney cancer	0.000389	0.00129	CcSEcCtD
Lisuride—Confusional state—Capecitabine—kidney cancer	0.000386	0.00128	CcSEcCtD
Lisuride—Feeling abnormal—Paclitaxel—kidney cancer	0.000385	0.00128	CcSEcCtD
Lisuride—Infection—Capecitabine—kidney cancer	0.000381	0.00126	CcSEcCtD
Lisuride—Nervous system disorder—Capecitabine—kidney cancer	0.000376	0.00125	CcSEcCtD
Lisuride—Tachycardia—Capecitabine—kidney cancer	0.000374	0.00124	CcSEcCtD
Lisuride—Vomiting—Vincristine—kidney cancer	0.000374	0.00124	CcSEcCtD
Lisuride—Sweating—Doxorubicin—kidney cancer	0.000371	0.00123	CcSEcCtD
Lisuride—Hyperhidrosis—Capecitabine—kidney cancer	0.00037	0.00123	CcSEcCtD
Lisuride—Headache—Vincristine—kidney cancer	0.000368	0.00122	CcSEcCtD
Lisuride—Anorexia—Capecitabine—kidney cancer	0.000365	0.00121	CcSEcCtD
Lisuride—Vomiting—Gemcitabine—kidney cancer	0.000355	0.00118	CcSEcCtD
Lisuride—Headache—Gemcitabine—kidney cancer	0.000349	0.00116	CcSEcCtD
Lisuride—Insomnia—Capecitabine—kidney cancer	0.000347	0.00115	CcSEcCtD
Lisuride—Oedema peripheral—Doxorubicin—kidney cancer	0.000342	0.00114	CcSEcCtD
Lisuride—Dyspnoea—Capecitabine—kidney cancer	0.000342	0.00114	CcSEcCtD
Lisuride—Asthenia—Paclitaxel—kidney cancer	0.000335	0.00111	CcSEcCtD
Lisuride—Decreased appetite—Capecitabine—kidney cancer	0.000333	0.00111	CcSEcCtD
Lisuride—Gastrointestinal disorder—Capecitabine—kidney cancer	0.000331	0.0011	CcSEcCtD
Lisuride—Fatigue—Capecitabine—kidney cancer	0.00033	0.0011	CcSEcCtD
Lisuride—Constipation—Capecitabine—kidney cancer	0.000328	0.00109	CcSEcCtD
Lisuride—Cardiac disorder—Doxorubicin—kidney cancer	0.000323	0.00107	CcSEcCtD
Lisuride—Feeling abnormal—Capecitabine—kidney cancer	0.000316	0.00105	CcSEcCtD
Lisuride—Angiopathy—Doxorubicin—kidney cancer	0.000315	0.00105	CcSEcCtD
Lisuride—Immune system disorder—Doxorubicin—kidney cancer	0.000314	0.00104	CcSEcCtD
Lisuride—Mediastinal disorder—Doxorubicin—kidney cancer	0.000313	0.00104	CcSEcCtD
Lisuride—Dizziness—Paclitaxel—kidney cancer	0.000309	0.00103	CcSEcCtD
Lisuride—Mental disorder—Doxorubicin—kidney cancer	0.000305	0.00101	CcSEcCtD
Lisuride—Malnutrition—Doxorubicin—kidney cancer	0.000303	0.00101	CcSEcCtD
Lisuride—Vomiting—Paclitaxel—kidney cancer	0.000297	0.000986	CcSEcCtD
Lisuride—Headache—Paclitaxel—kidney cancer	0.000292	0.000972	CcSEcCtD
Lisuride—Asthenia—Capecitabine—kidney cancer	0.000275	0.000913	CcSEcCtD
Lisuride—Vertigo—Doxorubicin—kidney cancer	0.000272	0.000903	CcSEcCtD
Lisuride—Syncope—Doxorubicin—kidney cancer	0.000271	0.000902	CcSEcCtD
Lisuride—Palpitations—Doxorubicin—kidney cancer	0.000267	0.000889	CcSEcCtD
Lisuride—Cough—Doxorubicin—kidney cancer	0.000264	0.000877	CcSEcCtD
Lisuride—Anxiety—Doxorubicin—kidney cancer	0.000257	0.000853	CcSEcCtD
Lisuride—Dizziness—Capecitabine—kidney cancer	0.000253	0.000842	CcSEcCtD
Lisuride—Dry mouth—Doxorubicin—kidney cancer	0.000252	0.000837	CcSEcCtD
Lisuride—Confusional state—Doxorubicin—kidney cancer	0.000249	0.000827	CcSEcCtD
Lisuride—Infection—Doxorubicin—kidney cancer	0.000245	0.000815	CcSEcCtD
Lisuride—Vomiting—Capecitabine—kidney cancer	0.000244	0.000809	CcSEcCtD
Lisuride—Nervous system disorder—Doxorubicin—kidney cancer	0.000242	0.000805	CcSEcCtD
Lisuride—Tachycardia—Doxorubicin—kidney cancer	0.000241	0.000801	CcSEcCtD
Lisuride—Headache—Capecitabine—kidney cancer	0.00024	0.000798	CcSEcCtD
Lisuride—Hyperhidrosis—Doxorubicin—kidney cancer	0.000239	0.000793	CcSEcCtD
Lisuride—Anorexia—Doxorubicin—kidney cancer	0.000235	0.000782	CcSEcCtD
Lisuride—Insomnia—Doxorubicin—kidney cancer	0.000223	0.000742	CcSEcCtD
Lisuride—Dyspnoea—Doxorubicin—kidney cancer	0.00022	0.000732	CcSEcCtD
Lisuride—Somnolence—Doxorubicin—kidney cancer	0.00022	0.00073	CcSEcCtD
Lisuride—Decreased appetite—Doxorubicin—kidney cancer	0.000215	0.000713	CcSEcCtD
Lisuride—Gastrointestinal disorder—Doxorubicin—kidney cancer	0.000213	0.000708	CcSEcCtD
Lisuride—Fatigue—Doxorubicin—kidney cancer	0.000213	0.000708	CcSEcCtD
Lisuride—Constipation—Doxorubicin—kidney cancer	0.000211	0.000702	CcSEcCtD
Lisuride—Feeling abnormal—Doxorubicin—kidney cancer	0.000204	0.000676	CcSEcCtD
Lisuride—Asthenia—Doxorubicin—kidney cancer	0.000177	0.000589	CcSEcCtD
Lisuride—Dizziness—Doxorubicin—kidney cancer	0.000163	0.000543	CcSEcCtD
Lisuride—Vomiting—Doxorubicin—kidney cancer	0.000157	0.000522	CcSEcCtD
Lisuride—Headache—Doxorubicin—kidney cancer	0.000155	0.000514	CcSEcCtD
Lisuride—HTR2A—urine—kidney cancer	0.00015	0.0995	CbGeAlD
Lisuride—CYP3A4—urine—kidney cancer	0.000138	0.0921	CbGeAlD
Lisuride—CYP2D6—urine—kidney cancer	0.000136	0.0907	CbGeAlD
Lisuride—ADRA1B—renal system—kidney cancer	0.000101	0.067	CbGeAlD
Lisuride—ADRA1B—kidney—kidney cancer	9.74e-05	0.0648	CbGeAlD
Lisuride—Ergonovine—ABCB1—kidney cancer	9.56e-05	0.64	CrCbGaD
Lisuride—HTR1D—kidney—kidney cancer	7.12e-05	0.0474	CbGeAlD
Lisuride—HTR2B—cortex of kidney—kidney cancer	6.45e-05	0.0429	CbGeAlD
Lisuride—ADRB1—cardiac atrium—kidney cancer	6.41e-05	0.0427	CbGeAlD
Lisuride—HTR1A—renal system—kidney cancer	6.14e-05	0.0409	CbGeAlD
Lisuride—ADRA2C—nephron tubule—kidney cancer	5.93e-05	0.0395	CbGeAlD
Lisuride—ADRA2C—renal system—kidney cancer	5.39e-05	0.0359	CbGeAlD
Lisuride—Ergotamine—ABCB1—kidney cancer	5.38e-05	0.36	CrCbGaD
Lisuride—ADRA2C—kidney—kidney cancer	5.21e-05	0.0347	CbGeAlD
Lisuride—ADRA2C—cortex of kidney—kidney cancer	5.08e-05	0.0338	CbGeAlD
Lisuride—ADRA2C—cardiac atrium—kidney cancer	4.83e-05	0.0321	CbGeAlD
Lisuride—ADRA2A—cortex of kidney—kidney cancer	4.05e-05	0.027	CbGeAlD
Lisuride—ADRA2A—gonad—kidney cancer	3.86e-05	0.0257	CbGeAlD
Lisuride—ADRA2A—cardiac atrium—kidney cancer	3.85e-05	0.0256	CbGeAlD
Lisuride—HTR2A—renal system—kidney cancer	3.66e-05	0.0243	CbGeAlD
Lisuride—HTR2A—kidney—kidney cancer	3.54e-05	0.0235	CbGeAlD
Lisuride—CYP3A4—renal system—kidney cancer	3.39e-05	0.0225	CbGeAlD
Lisuride—CYP2D6—renal system—kidney cancer	3.33e-05	0.0222	CbGeAlD
Lisuride—HTR2A—gonad—kidney cancer	3.28e-05	0.0218	CbGeAlD
Lisuride—CYP3A4—kidney—kidney cancer	3.27e-05	0.0218	CbGeAlD
Lisuride—CYP2D6—kidney—kidney cancer	3.22e-05	0.0214	CbGeAlD
Lisuride—DRD1—Signaling Pathways—CCND1—kidney cancer	6.78e-06	0.000115	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—JUN—kidney cancer	6.76e-06	0.000114	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—MTOR—kidney cancer	6.74e-06	0.000114	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—PTGS1—kidney cancer	6.74e-06	0.000114	CbGpPWpGaD
Lisuride—DRD5—Signaling Pathways—TP53—kidney cancer	6.72e-06	0.000114	CbGpPWpGaD
Lisuride—HTR1A—Signaling by GPCR—PIK3CA—kidney cancer	6.72e-06	0.000114	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—CTNNB1—kidney cancer	6.71e-06	0.000114	CbGpPWpGaD
Lisuride—HTR2A—Signaling by GPCR—MAPK1—kidney cancer	6.69e-06	0.000113	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—CCND1—kidney cancer	6.69e-06	0.000113	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—CCND1—kidney cancer	6.69e-06	0.000113	CbGpPWpGaD
Lisuride—HTR2C—Signaling by GPCR—PIK3CA—kidney cancer	6.68e-06	0.000113	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—APC—kidney cancer	6.68e-06	0.000113	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—KIT—kidney cancer	6.68e-06	0.000113	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—JUN—kidney cancer	6.67e-06	0.000113	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—JUN—kidney cancer	6.67e-06	0.000113	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—VEGFA—kidney cancer	6.67e-06	0.000113	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—RAF1—kidney cancer	6.67e-06	0.000113	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—CYP1A1—kidney cancer	6.64e-06	0.000112	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—RELA—kidney cancer	6.64e-06	0.000112	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—RAF1—kidney cancer	6.63e-06	0.000112	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—CTNNB1—kidney cancer	6.62e-06	0.000112	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—CTNNB1—kidney cancer	6.62e-06	0.000112	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—PSMD7—kidney cancer	6.61e-06	0.000112	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—RELA—kidney cancer	6.6e-06	0.000112	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—ERBB2—kidney cancer	6.59e-06	0.000112	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—VEGFA—kidney cancer	6.56e-06	0.000111	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—ERBB2—kidney cancer	6.56e-06	0.000111	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—PTEN—kidney cancer	6.54e-06	0.000111	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—MTOR—kidney cancer	6.51e-06	0.00011	CbGpPWpGaD
Lisuride—ADRA2C—Metabolism—PTEN—kidney cancer	6.51e-06	0.00011	CbGpPWpGaD
Lisuride—ADRA2C—Signaling by GPCR—PIK3CA—kidney cancer	6.5e-06	0.00011	CbGpPWpGaD
Lisuride—DRD2—GPCR downstream signaling—PIK3CA—kidney cancer	6.49e-06	0.00011	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—MTOR—kidney cancer	6.47e-06	0.00011	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—PTEN—kidney cancer	6.45e-06	0.000109	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—PTEN—kidney cancer	6.45e-06	0.000109	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—RAF1—kidney cancer	6.45e-06	0.000109	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—MAPK3—kidney cancer	6.44e-06	0.000109	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—RELA—kidney cancer	6.42e-06	0.000109	CbGpPWpGaD
Lisuride—DRD2—Signaling by GPCR—KRAS—kidney cancer	6.42e-06	0.000109	CbGpPWpGaD
Lisuride—ADRA1B—Signaling by GPCR—PIK3CA—kidney cancer	6.4e-06	0.000108	CbGpPWpGaD
Lisuride—ADRA2A—Signaling by GPCR—MAPK3—kidney cancer	6.39e-06	0.000108	CbGpPWpGaD
Lisuride—HTR2A—GPCR downstream signaling—PIK3CA—kidney cancer	6.39e-06	0.000108	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—CDKN1B—kidney cancer	6.39e-06	0.000108	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—ERBB2—kidney cancer	6.38e-06	0.000108	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—POMC—kidney cancer	6.35e-06	0.000108	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—RAF1—kidney cancer	6.35e-06	0.000107	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—CDKN1B—kidney cancer	6.33e-06	0.000107	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—RELA—kidney cancer	6.32e-06	0.000107	CbGpPWpGaD
Lisuride—HTR2A—Signaling by GPCR—KRAS—kidney cancer	6.32e-06	0.000107	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—MAPK3—kidney cancer	6.31e-06	0.000107	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—MTOR—kidney cancer	6.3e-06	0.000107	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—ERBB2—kidney cancer	6.28e-06	0.000106	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—BRAF—kidney cancer	6.27e-06	0.000106	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—MYC—kidney cancer	6.27e-06	0.000106	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—BCHE—kidney cancer	6.26e-06	0.000106	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—VEGFA—kidney cancer	6.26e-06	0.000106	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—IL2—kidney cancer	6.25e-06	0.000106	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—MAPK3—kidney cancer	6.21e-06	0.000105	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—MTOR—kidney cancer	6.2e-06	0.000105	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—IL2—kidney cancer	6.19e-06	0.000105	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—SLC5A5—kidney cancer	6.19e-06	0.000105	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—MYC—kidney cancer	6.13e-06	0.000104	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—MAPK1—kidney cancer	6.13e-06	0.000104	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—CDKN1B—kidney cancer	6.11e-06	0.000103	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—CCND1—kidney cancer	6.09e-06	0.000103	CbGpPWpGaD
Lisuride—ADRA2A—Signaling by GPCR—MAPK1—kidney cancer	6.08e-06	0.000103	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—JUN—kidney cancer	6.08e-06	0.000103	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—CDKN1B—kidney cancer	6.08e-06	0.000103	CbGpPWpGaD
Lisuride—ADRA2A—Metabolism—PTGS2—kidney cancer	6.06e-06	0.000103	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—MYC—kidney cancer	6.04e-06	0.000102	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—CCND1—kidney cancer	6.04e-06	0.000102	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—CTNNB1—kidney cancer	6.03e-06	0.000102	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—JUN—kidney cancer	6.02e-06	0.000102	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—MAPK1—kidney cancer	6e-06	0.000102	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—CTNNB1—kidney cancer	5.98e-06	0.000101	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—IL2—kidney cancer	5.98e-06	0.000101	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—SLC2A1—kidney cancer	5.98e-06	0.000101	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—IL2—kidney cancer	5.95e-06	0.000101	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—MAPK3—kidney cancer	5.93e-06	0.0001	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—CDKN1B—kidney cancer	5.91e-06	0.0001	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—VEGFA—kidney cancer	5.91e-06	0.0001	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—MAPK1—kidney cancer	5.91e-06	9.99e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling by GPCR—PIK3CA—kidney cancer	5.9e-06	9.98e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—PTEN—kidney cancer	5.88e-06	9.95e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—RAF1—kidney cancer	5.85e-06	9.9e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—VEGFA—kidney cancer	5.83e-06	9.86e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—VEGFA—kidney cancer	5.83e-06	9.86e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—RELA—kidney cancer	5.83e-06	9.86e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—CCND1—kidney cancer	5.83e-06	9.86e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—PTEN—kidney cancer	5.83e-06	9.86e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—CDKN1B—kidney cancer	5.82e-06	9.84e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—JUN—kidney cancer	5.81e-06	9.84e-05	CbGpPWpGaD
Lisuride—ADRA2A—GPCR downstream signaling—PIK3CA—kidney cancer	5.81e-06	9.84e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling by GPCR—PIK3CA—kidney cancer	5.8e-06	9.82e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—CCND1—kidney cancer	5.8e-06	9.81e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—ERBB2—kidney cancer	5.79e-06	9.8e-05	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—KRAS—kidney cancer	5.79e-06	9.8e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—JUN—kidney cancer	5.78e-06	9.79e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—IL2—kidney cancer	5.78e-06	9.79e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—CTNNB1—kidney cancer	5.77e-06	9.76e-05	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—MYC—kidney cancer	5.76e-06	9.75e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—RAF1—kidney cancer	5.76e-06	9.74e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling by GPCR—KRAS—kidney cancer	5.75e-06	9.72e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—CTNNB1—kidney cancer	5.74e-06	9.71e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—RELA—kidney cancer	5.73e-06	9.7e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—MTOR—kidney cancer	5.71e-06	9.67e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—ERBB2—kidney cancer	5.7e-06	9.64e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—IL2—kidney cancer	5.69e-06	9.63e-05	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—KRAS—kidney cancer	5.67e-06	9.59e-05	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—MAPK1—kidney cancer	5.64e-06	9.54e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—CCND1—kidney cancer	5.64e-06	9.54e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—JUN—kidney cancer	5.63e-06	9.52e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—PTEN—kidney cancer	5.62e-06	9.52e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—MTOR—kidney cancer	5.62e-06	9.51e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—PTEN—kidney cancer	5.59e-06	9.47e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—MAPK3—kidney cancer	5.59e-06	9.46e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—CTNNB1—kidney cancer	5.58e-06	9.45e-05	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—KRAS—kidney cancer	5.58e-06	9.44e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—CCND1—kidney cancer	5.55e-06	9.39e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—JUN—kidney cancer	5.54e-06	9.37e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—MAPK3—kidney cancer	5.51e-06	9.33e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—MAPK3—kidney cancer	5.51e-06	9.33e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—CTNNB1—kidney cancer	5.49e-06	9.3e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—PTEN—kidney cancer	5.44e-06	9.21e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—MYC—kidney cancer	5.43e-06	9.2e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—MYC—kidney cancer	5.36e-06	9.07e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—CDKN1B—kidney cancer	5.36e-06	9.07e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—MYC—kidney cancer	5.36e-06	9.07e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—PTEN—kidney cancer	5.36e-06	9.06e-05	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—KRAS—kidney cancer	5.32e-06	9.01e-05	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—PIK3CA—kidney cancer	5.32e-06	9e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—MAPK1—kidney cancer	5.32e-06	9e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—VEGFA—kidney cancer	5.31e-06	8.99e-05	CbGpPWpGaD
Lisuride—ADRA2A—Metabolism—PTEN—kidney cancer	5.29e-06	8.94e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling by GPCR—PIK3CA—kidney cancer	5.28e-06	8.93e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—CDKN1B—kidney cancer	5.28e-06	8.93e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—VEGFA—kidney cancer	5.26e-06	8.9e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—IL2—kidney cancer	5.25e-06	8.88e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—MAPK1—kidney cancer	5.25e-06	8.88e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—MAPK1—kidney cancer	5.25e-06	8.88e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—RAF1—kidney cancer	5.24e-06	8.87e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—RELA—kidney cancer	5.22e-06	8.83e-05	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—PIK3CA—kidney cancer	5.21e-06	8.81e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—ERBB2—kidney cancer	5.18e-06	8.77e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—IL2—kidney cancer	5.16e-06	8.74e-05	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—TP53—kidney cancer	5.15e-06	8.71e-05	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—PIK3CA—kidney cancer	5.12e-06	8.67e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—CCND1—kidney cancer	5.12e-06	8.66e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—MTOR—kidney cancer	5.12e-06	8.66e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—JUN—kidney cancer	5.1e-06	8.64e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—VEGFA—kidney cancer	5.08e-06	8.6e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—CTNNB1—kidney cancer	5.07e-06	8.57e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—VEGFA—kidney cancer	5.05e-06	8.55e-05	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—TP53—kidney cancer	5.04e-06	8.53e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—CCND1—kidney cancer	5.03e-06	8.52e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—MAPK3—kidney cancer	5.02e-06	8.5e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—JUN—kidney cancer	5.02e-06	8.5e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—KRAS—kidney cancer	5.02e-06	8.5e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—CTNNB1—kidney cancer	4.98e-06	8.43e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—GSTP1—kidney cancer	4.98e-06	8.43e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—MAPK3—kidney cancer	4.98e-06	8.42e-05	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—TP53—kidney cancer	4.96e-06	8.39e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—KRAS—kidney cancer	4.95e-06	8.38e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—KRAS—kidney cancer	4.95e-06	8.38e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—POMC—kidney cancer	4.95e-06	8.38e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—PTEN—kidney cancer	4.94e-06	8.36e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—VEGFA—kidney cancer	4.92e-06	8.32e-05	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—PIK3CA—kidney cancer	4.89e-06	8.28e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—MYC—kidney cancer	4.89e-06	8.27e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—PTEN—kidney cancer	4.86e-06	8.22e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—MYC—kidney cancer	4.84e-06	8.19e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—VEGFA—kidney cancer	4.84e-06	8.19e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—MAPK3—kidney cancer	4.81e-06	8.13e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—CDKN1B—kidney cancer	4.8e-06	8.12e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—MAPK3—kidney cancer	4.78e-06	8.09e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—MAPK1—kidney cancer	4.78e-06	8.09e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—MAPK1—kidney cancer	4.74e-06	8.01e-05	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—TP53—kidney cancer	4.73e-06	8.01e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—ABCB1—kidney cancer	4.72e-06	7.98e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—IL2—kidney cancer	4.7e-06	7.95e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—MYC—kidney cancer	4.67e-06	7.91e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—MAPK3—kidney cancer	4.65e-06	7.87e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—MYC—kidney cancer	4.65e-06	7.87e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—PIK3CA—kidney cancer	4.61e-06	7.81e-05	CbGpPWpGaD
Lisuride—ADRA2C—Metabolism—PIK3CA—kidney cancer	4.59e-06	7.77e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—GSTM1—kidney cancer	4.58e-06	7.75e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—CCND1—kidney cancer	4.58e-06	7.75e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—MAPK3—kidney cancer	4.58e-06	7.74e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—MAPK1—kidney cancer	4.57e-06	7.74e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—JUN—kidney cancer	4.57e-06	7.73e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—PIK3CA—kidney cancer	4.55e-06	7.7e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—PIK3CA—kidney cancer	4.55e-06	7.7e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—MAPK1—kidney cancer	4.55e-06	7.7e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—CTNNB1—kidney cancer	4.53e-06	7.67e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—MYC—kidney cancer	4.52e-06	7.65e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—KRAS—kidney cancer	4.51e-06	7.64e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—KRAS—kidney cancer	4.47e-06	7.57e-05	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—TP53—kidney cancer	4.46e-06	7.55e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—VEGFA—kidney cancer	4.46e-06	7.55e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—MYC—kidney cancer	4.45e-06	7.53e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—MAPK1—kidney cancer	4.42e-06	7.49e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—PTEN—kidney cancer	4.42e-06	7.48e-05	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—TP53—kidney cancer	4.4e-06	7.45e-05	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—TP53—kidney cancer	4.4e-06	7.45e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—VEGFA—kidney cancer	4.39e-06	7.43e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—MAPK1—kidney cancer	4.35e-06	7.37e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—CYP1A1—kidney cancer	4.34e-06	7.35e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—KRAS—kidney cancer	4.32e-06	7.31e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—KRAS—kidney cancer	4.3e-06	7.27e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—MAPK3—kidney cancer	4.22e-06	7.14e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—KRAS—kidney cancer	4.18e-06	7.07e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—MAPK3—kidney cancer	4.15e-06	7.02e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—PIK3CA—kidney cancer	4.15e-06	7.02e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—KRAS—kidney cancer	4.11e-06	6.96e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—PIK3CA—kidney cancer	4.11e-06	6.95e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—MYC—kidney cancer	4.1e-06	6.94e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—MYC—kidney cancer	4.04e-06	6.83e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—MAPK1—kidney cancer	4.01e-06	6.79e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—TP53—kidney cancer	4.01e-06	6.79e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—VEGFA—kidney cancer	3.99e-06	6.76e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—TP53—kidney cancer	3.98e-06	6.73e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—PIK3CA—kidney cancer	3.97e-06	6.71e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—MAPK1—kidney cancer	3.95e-06	6.68e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—PTGS2—kidney cancer	3.95e-06	6.68e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—PIK3CA—kidney cancer	3.95e-06	6.68e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—PIK3CA—kidney cancer	3.84e-06	6.5e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—TP53—kidney cancer	3.84e-06	6.49e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—TP53—kidney cancer	3.82e-06	6.46e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—KRAS—kidney cancer	3.79e-06	6.42e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—PIK3CA—kidney cancer	3.78e-06	6.39e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—MAPK3—kidney cancer	3.78e-06	6.39e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—KRAS—kidney cancer	3.73e-06	6.31e-05	CbGpPWpGaD
Lisuride—ADRA2A—Metabolism—PIK3CA—kidney cancer	3.73e-06	6.31e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—TP53—kidney cancer	3.71e-06	6.28e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—MYC—kidney cancer	3.67e-06	6.22e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—TP53—kidney cancer	3.66e-06	6.19e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—MAPK1—kidney cancer	3.59e-06	6.08e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—PIK3CA—kidney cancer	3.48e-06	5.89e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—PTEN—kidney cancer	3.44e-06	5.83e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—PIK3CA—kidney cancer	3.43e-06	5.8e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—KRAS—kidney cancer	3.39e-06	5.74e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—TP53—kidney cancer	3.37e-06	5.7e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—TP53—kidney cancer	3.32e-06	5.61e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—POMC—kidney cancer	3.24e-06	5.48e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—PIK3CA—kidney cancer	3.12e-06	5.28e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—TP53—kidney cancer	3.02e-06	5.1e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—PTGS2—kidney cancer	2.58e-06	4.37e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—PIK3CA—kidney cancer	2.43e-06	4.11e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—PTEN—kidney cancer	2.25e-06	3.81e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—PIK3CA—kidney cancer	1.59e-06	2.69e-05	CbGpPWpGaD
